The company holds several patents for the composition and use of BCG combined with Anktiva in bladder cancer treatment. The rBCG vaccine, originally developed as a live vaccine against ...

The following is a summary of “Factors predicting local or systemic side effects related to intravesical BCG (Bacillus ...

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

BLADDER cancer is classified as either non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) ...

Today, the conventional treatment for non-invasive bladder cancer is immunotherapy with BCG (Bacillus Calmette-Guérin), a weakened bacterium that is introduced into the bladder to stimulate an ...

After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for ... combination with the BCG vaccine in non-muscle invasive bladder cancer (NMIBC) patients ...

In bladder cancer clinical trials in Europe, the recombinant BCG vaccine has demonstrated potent ... potential benefits to patients, potential treatment outcomes for patients, the described ...

In bladder cancer clinical trials in Europe, the recombinant BCG vaccine has demonstrated potent ... potential benefits to patients, potential treatment outcomes for patients, the described ...

ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's potential. See more here.

In bladder cancer clinical trials in Europe, the recombinant BCG vaccine has demonstrated potent ... potential benefits to patients, potential treatment outcomes for patients, the described ...